{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:37:28Z","timestamp":1773707848456,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,8,31]],"date-time":"2015-08-31T00:00:00Z","timestamp":1440979200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1038\/npp.2015.267","type":"journal-article","created":{"date-parts":[[2015,8,31]],"date-time":"2015-08-31T11:05:00Z","timestamp":1441019100000},"page":"1179-1187","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Rapid Recovery of Vesicular Dopamine Levels in Methamphetamine Users in Early Abstinence"],"prefix":"10.1038","volume":"41","author":[{"given":"Isabelle","family":"Boileau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"McCluskey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junchao","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Houle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J","family":"Kish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,31]]},"reference":[{"key":"BFnpp2015267_CR1","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/syn.20743","volume":"64","author":"I Boileau","year":"2010","unstructured":"Boileau I, Houle S, Rusjan PM, Furukawa Y, Wilkins D, Tong J et al (2010). Influence of a low dose of amphetamine on vesicular monoamine transporter binding: a PET (+)[11C]DTBZ study in humans. Synapse 64: 417\u2013420.","journal-title":"Synapse"},{"key":"BFnpp2015267_CR2","doi-asserted-by":"publisher","first-page":"9850","DOI":"10.1523\/JNEUROSCI.3008-08.2008","volume":"28","author":"I Boileau","year":"2008","unstructured":"Boileau I, Rusjan P, Houle S, Wilkins D, Tong J, Selby P et al (2008). Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: is VMAT2 a stable dopamine neuron biomarker? J Neurosci 28: 9850\u20139856.","journal-title":"J Neurosci"},{"key":"BFnpp2015267_CR3","first-page":"283","volume":"40","author":"GL Chan","year":"1999","unstructured":"Chan GL, Holden JE, Stoessl AJ, Samii A, Doudet DJ, Dobko T et al (1999). Reproducibility studies with 11C-DTBZ, a monoamine vesicular transporter inhibitor in healthy human subjects. J Nucl Med 40: 283\u2013289.","journal-title":"J Nucl Med"},{"key":"BFnpp2015267_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/syn.10199","volume":"49","author":"R de La Fuente-Fernandez","year":"2003","unstructured":"de La Fuente-Fernandez R, Furtado S, Guttman M, Furukawa Y, Lee CS, Calne DB et al (2003). VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET. Synapse 49: 20\u201328.","journal-title":"Synapse"},{"key":"BFnpp2015267_CR5","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/syn.20653","volume":"63","author":"R de la Fuente-Fernandez","year":"2009","unstructured":"de la Fuente-Fernandez R, Sossi V, McCormick S, Schulzer M, Ruth TJ, Stoessl AJ (2009). Visualizing vesicular dopamine dynamics in Parkinson's disease. Synapse 63: 713\u2013716.","journal-title":"Synapse"},{"key":"BFnpp2015267_CR6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1109\/42.563660","volume":"16","author":"M Defrise","year":"1997","unstructured":"Defrise M, Kinahan PE, Townsend DW, Michel C, Sibomana M, Newport DF (1997). Exact and approximate rebinning algorithms for 3-D PET data. IEEE Trans Med Imag 16: 145\u2013158.","journal-title":"IEEE Trans Med Imag"},{"key":"BFnpp2015267_CR7","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1007\/BF01485901","volume":"38","author":"H Ehringer","year":"1960","unstructured":"Ehringer H, Hornykiewicz O (1960). Verteilung von noradrenalin und dopamin (3-hydroxytyramin) im gehirn des menches und ihr verhalten bei erkrankungen des extrapyramiden systems. Klin Wochenschr 38: 1236\u20131239.","journal-title":"Klin Wochenschr"},{"key":"BFnpp2015267_CR8","unstructured":"First MB, Spitzer RL, Gibbon M, Williams JBW (1995). Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition. (SCID\/NP) New York: Biometrics Research, New York State Psychiatric Institute; (November 2002)."},{"key":"BFnpp2015267_CR9","first-page":"237","volume":"86","author":"KA Frey","year":"2001","unstructured":"Frey KA, Koeppe RA, Kilbourn MR (2001). Imaging the vesicular monoamine transporter. Adv Neurol 86: 237\u2013247.","journal-title":"Adv Neurol"},{"key":"BFnpp2015267_CR10","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/ana.410400609","volume":"40","author":"KA Frey","year":"1996","unstructured":"Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, Gilman S et al (1996). Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol 40: 873\u2013884.","journal-title":"Ann Neurol"},{"key":"BFnpp2015267_CR11","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1006\/nimg.1997.0303","volume":"6","author":"RN Gunn","year":"1997","unstructured":"Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ (1997). Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 6: 279\u2013287.","journal-title":"Neuroimage"},{"key":"BFnpp2015267_CR12","first-page":"1","volume":"86","author":"O Hornykiewicz","year":"2001","unstructured":"Hornykiewicz O (2001). Dopamine and Parkinson\u2019s disease. A personal view of the past, the present, and the future. Adv Neurol 86: 1\u201311.","journal-title":"Adv Neurol"},{"key":"BFnpp2015267_CR13","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00213-006-0330-6","volume":"185","author":"CE Johanson","year":"2006","unstructured":"Johanson CE, Frey KA, Lundahl LH, Keenan P, Lockhart N, Roll J et al (2006). Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers. Psychopharmacology 185: 327\u2013338.","journal-title":"Psychopharmacology"},{"key":"BFnpp2015267_CR14","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1520\/JFS2003401","volume":"49","author":"KS Kalasinsky","year":"2004","unstructured":"Kalasinsky KS, Hugel J, Kish SJ (2004). Use of MDA (the \u2018love drug\u2019) and methamphetamine in Toronto by unsuspecting users of ecstasy (MDMA). J Forensic Sci 49: 1106\u20131112.","journal-title":"J Forensic Sci"},{"key":"BFnpp2015267_CR15","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1046\/j.1360-0443.2002.00121.x","volume":"97","author":"S Kaye","year":"2002","unstructured":"Kaye S, Darke S (2002). Determining a diagnostic cut-off on the Severity of Dependence Scale (SDS) for cocaine dependence. Addiction 97: 727\u2013731.","journal-title":"Addiction"},{"key":"BFnpp2015267_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.nucmedbio.2009.08.013","volume":"37","author":"MR Kilbourn","year":"2010","unstructured":"Kilbourn MR, Butch ER, Desmond T, Sherman P, Harris PE, Frey KA (2010). In vivo [11C]dihydrotetrabenazine binding in rat striatum: sensitivity to dopamine concentrations. Nucl Med Biol 37: 3\u20138.","journal-title":"Nucl Med Biol"},{"key":"BFnpp2015267_CR17","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1503\/cmaj.071675","volume":"178","author":"SJ Kish","year":"2008","unstructured":"Kish SJ (2008). Pharmacologic mechanisms of crystal meth. Cmaj 178: 1679\u20131682.","journal-title":"Cmaj"},{"key":"BFnpp2015267_CR18","volume-title":"Chapter 08: The Pathology of Methamphetamine Use in the Human Brain From: The Effects of Drug Abuse on the Human Nervous System","author":"SJ Kish","year":"2014","unstructured":"Kish SJ (2014) Chapter 08: The Pathology of Methamphetamine Use in the Human Brain From: The Effects of Drug Abuse on the Human Nervous System, edited by Bertha Madras and Michael Kuhar. Elsevier: Amsterdam, The Netherlands."},{"key":"BFnpp2015267_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00414-006-0087-9","volume":"121","author":"O Kitamura","year":"2007","unstructured":"Kitamura O, Tokunaga I, Gotohda T, Kubo S (2007). Immunohistochemical investigation of dopaminergic terminal markers and caspase-3 activation in the striatum of human methamphetamine users. Int J Legal Med 121: 163\u2013168.","journal-title":"Int J Legal Med"},{"key":"BFnpp2015267_CR20","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1097\/00004647-199611000-00025","volume":"16","author":"RA Koeppe","year":"1996","unstructured":"Koeppe RA, Frey KA, Vander Borght TM, Karlamangla A, Jewett DM, Lee LC et al (1996). Kinetic evaluation of [11C]dihydrotetrabenazine by dynamic PET: measurement of vesicular monoamine transporter. J Cereb Blood Flow Metab 16: 1288\u20131299.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"Part 1","key":"BFnpp2015267_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1006\/nimg.1996.0066","volume":"4","author":"AA Lammertsma","year":"1996","unstructured":"Lammertsma AA, Hume SP (1996). Simplified reference tissue model for PET receptor studies. Neuroimage 4 (Part 1): 153\u2013158.","journal-title":"Neuroimage"},{"key":"BFnpp2015267_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/mds.26120","volume":"30","author":"AJ Lees","year":"2014","unstructured":"Lees AJ, Tolosa E, Olanow CW (2014). Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. Mov Disord 30: 19\u201336.","journal-title":"Mov Disord"},{"key":"BFnpp2015267_CR23","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/01.WCB.0000048520.34839.1A","volume":"23","author":"D Martinez","year":"2003","unstructured":"Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y et al (2003). Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 23: 285\u2013300.","journal-title":"J Cereb Blood Flow Metab"},{"key":"BFnpp2015267_CR24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/syn.20471","volume":"62","author":"UD McCann","year":"2008","unstructured":"McCann UD, Kuwabara H, Kumar A, Palermo M, Abbey R, Brasic J et al (2008). Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. Synapse 62: 91\u2013100.","journal-title":"Synapse"},{"key":"BFnpp2015267_CR25","doi-asserted-by":"publisher","first-page":"8417","DOI":"10.1523\/JNEUROSCI.18-20-08417.1998","volume":"18","author":"UD McCann","year":"1998","unstructured":"McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA (1998). Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci 18: 8417\u20138422.","journal-title":"J Neurosci"},{"key":"BFnpp2015267_CR26","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1111\/j.1360-0443.2005.01160.x","volume":"100","author":"C McGregor","year":"2005","unstructured":"McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White JM (2005). The nature, time course and severity of methamphetamine withdrawal. Addiction 100: 1320\u20131329.","journal-title":"Addiction"},{"issue":"Part 2","key":"BFnpp2015267_CR27","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1093\/brain\/awh046","volume":"127","author":"A Moszczynska","year":"2004","unstructured":"Moszczynska A, Fitzmaurice P, Ang L, Kalasinsky KS, Schmunk GA, Peretti FJ et al (2004). Why is parkinsonism not a feature of human methamphetamine users? Brain 127 (Part 2): 363.","journal-title":"Brain"},{"issue":"Pt 11","key":"BFnpp2015267_CR28","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1093\/brain\/awr233","volume":"134","author":"R Nandhagopal","year":"2011","unstructured":"Nandhagopal R, Kuramoto L, Schulzer M, Mak E, Cragg J, McKenzie J et al (2011). Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. Brain 134 (Pt 11): 3290\u20133298.","journal-title":"Brain"},{"key":"BFnpp2015267_CR29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1176\/appi.ajp.2011.11010126","volume":"169","author":"R Narendran","year":"2012","unstructured":"Narendran R, Lopresti BJ, Martinez D, Mason NS, Himes M, May MA et al (2012). In vivo evidence for low striatal vesicular monoamine transporter 2 (VMAT2) availability in cocaine abusers. Am J Psychiatry 169: 55\u201363.","journal-title":"Am J Psychiatry"},{"key":"BFnpp2015267_CR30","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1124\/jpet.106.103622","volume":"319","author":"JS Partilla","year":"2006","unstructured":"Partilla JS, Dempsey AG, Nagpal AS, Blough BE, Baumann MH, Rothman RB (2006). Interaction of amphetamines and related compounds at the vesicular monoamine transporter. J Pharmacol Exp Ther 319: 237\u2013246.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFnpp2015267_CR31","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.pscychresns.2006.01.011","volume":"147","author":"P Rusjan","year":"2006","unstructured":"Rusjan P, Mamo D, Ginovart N, Hussey D, Vitcu I, Yasuno F et al (2006). An automated method for the extraction of regional data from PET images. Psychiatry Res 147: 79\u201389.","journal-title":"Psychiatry Res"},{"key":"BFnpp2015267_CR32","volume-title":"Neurotoxicity of Methamphetamine and Related Drugs","author":"LS Seiden","year":"1987","unstructured":"Seiden LS, Ricaurte GA (1987) Neurotoxicity of Methamphetamine and Related Drugs. Raven: New York, NY."},{"key":"BFnpp2015267_CR33","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1006\/brcg.1995.1258","volume":"28","author":"AE Taylor","year":"1995","unstructured":"Taylor AE, Saint-Cyr JA (1995). The neuropsychology of Parkinson's disease. Brain Cogn 28: 281\u2013296.","journal-title":"Brain Cogn"},{"key":"BFnpp2015267_CR34","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1111\/j.1471-4159.2009.06094.x","volume":"109","author":"DM Thomas","year":"2009","unstructured":"Thomas DM, Francescutti-Verbeem DM, Kuhn DM (2009). Increases in cytoplasmic dopamine compromise the normal resistance of the nucleus accumbens to methamphetamine neurotoxicity. J Neurochem 109: 1745\u20131755.","journal-title":"J Neurochem"},{"key":"BFnpp2015267_CR35","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1038\/jcbfm.2011.63","volume":"31","author":"J Tong","year":"2011","unstructured":"Tong J, Boileau I, Furukawa Y, Chang LJ, Wilson AA, Houle S et al (2011). Distribution of vesicular monoamine transporter 2 protein in human brain: implications for brain imaging studies. J Cereb Blood Flow Metab 31: 2065\u20132075.","journal-title":"J Cereb Blood Flow Metab"},{"key":"BFnpp2015267_CR36","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.nbd.2014.03.015","volume":"67","author":"J Tong","year":"2014","unstructured":"Tong J, Fitzmaurice P, Furukawa Y, Schmunk GA, Wickham DJ, Ang LC et al (2014). Is brain gliosis a characteristic of chronic methamphetamine use in the human? Neurobiol Dis 67: 107\u2013118.","journal-title":"Neurobiol Dis"},{"key":"BFnpp2015267_CR37","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/syn.20573","volume":"62","author":"J Tong","year":"2008","unstructured":"Tong J, Wilson AA, Boileau I, Houle S, Kish SJ (2008). Dopamine modulating drugs influence striatal (+)-[11C]DTBZ binding in rats: VMAT2 binding is sensitive to changes in vesicular dopamine concentration. Synapse 62: 873\u2013876.","journal-title":"Synapse"},{"key":"BFnpp2015267_CR38","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/j.1360-0443.1997.tb03647.x","volume":"92","author":"L Topp","year":"1997","unstructured":"Topp L, Mattick RP (1997). Validation of the amphetamine dependence syndrome and the SAmDQ. Addiction 92: 151\u2013162.","journal-title":"Addiction"},{"key":"BFnpp2015267_CR39","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/0014-2999(95)00594-3","volume":"294","author":"T Vander Borght","year":"1995","unstructured":"Vander Borght T, Kilbourn M, Desmond T, Kuhl D, Frey K (1995). The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 294: 577\u2013583.","journal-title":"Eur J Pharmacol"},{"key":"BFnpp2015267_CR40","doi-asserted-by":"publisher","first-page":"9414","DOI":"10.1523\/JNEUROSCI.21-23-09414.2001","volume":"21","author":"ND Volkow","year":"2001","unstructured":"Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler M et al (2001a). Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 21: 9414\u20139418.","journal-title":"J Neurosci"},{"key":"BFnpp2015267_CR41","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1176\/appi.ajp.158.3.377","volume":"158","author":"ND Volkow","year":"2001","unstructured":"Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D et al (2001b). Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158: 377\u2013382.","journal-title":"Am J Psychiatry"},{"key":"BFnpp2015267_CR42","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/mp.2011.86","volume":"17","author":"GJ Wang","year":"2012","unstructured":"Wang GJ, Smith L, Volkow ND, Telang F, Logan J, Tomasi D et al (2012). Decreased dopamine activity predicts relapse in methamphetamine abusers. Mol Psychiatry 17: 918\u2013925.","journal-title":"Mol Psychiatry"},{"key":"BFnpp2015267_CR43","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/nm0696-699","volume":"2","author":"JM Wilson","year":"1996","unstructured":"Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM et al (1996a). Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2: 699\u2013703.","journal-title":"Nat Med"},{"key":"BFnpp2015267_CR44","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/ana.410400312","volume":"40","author":"JM Wilson","year":"1996","unstructured":"Wilson JM, Levey AI, Bergeron C, Kalasinsky K, Ang L, Peretti F et al (1996b). Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann Neurol 40: 428\u2013439.","journal-title":"Ann Neurol"},{"key":"BFnpp2015267_CR45","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1212\/WNL.47.3.718","volume":"47","author":"JM Wilson","year":"1996","unstructured":"Wilson JM, Levey AI, Rajput A, Ang L, Guttman M, Shannak K et al (1996c). Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson\u2019s disease. Neurology 47: 718\u2013726.","journal-title":"Neurology"},{"key":"BFnpp2015267_CR46","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1111\/j.1360-0443.2010.03066.x","volume":"105","author":"T Zorick","year":"2010","unstructured":"Zorick T, Nestor L, Miotto K, Sugar C, Hellemann G, Scanlon G et al (2010). Withdrawal symptoms in abstinent methamphetamine-dependent subjects. Addiction 105: 1809\u20131818.","journal-title":"Addiction"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/npp2015267.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/npp2015267","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/npp2015267.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T23:53:00Z","timestamp":1684453980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/npp2015267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,31]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["BFnpp2015267"],"URL":"https:\/\/doi.org\/10.1038\/npp.2015.267","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,31]]},"assertion":[{"value":"8 June 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}